[go: up one dir, main page]

BR9711457A - Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. - Google Patents

Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.

Info

Publication number
BR9711457A
BR9711457A BR9711457-0A BR9711457A BR9711457A BR 9711457 A BR9711457 A BR 9711457A BR 9711457 A BR9711457 A BR 9711457A BR 9711457 A BR9711457 A BR 9711457A
Authority
BR
Brazil
Prior art keywords
diagnosis
treatment
compounds
mycobacterial infections
vaccae
Prior art date
Application number
BR9711457-0A
Other languages
English (en)
Inventor
Paul Tan
Jun Hiyama
Elizabeth S Visser
Margot A Skinner
Linda M Scott
Ross L Prestidge
Original Assignee
Genesis Research & Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Research & Dev Corp filed Critical Genesis Research & Dev Corp
Publication of BR9711457A publication Critical patent/BR9711457A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • A61K2039/55594Adjuvants of undefined constitution from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/863Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

"Patente de Invenção: <B>"COMPOSTOS E PROCESSO PARA O TRATAMENTO E DIAGNóSTICO DE INFECçõES MICOBACTERIANAS"<D>. A presente invenção provê polipeptídeos compreendendo uma porção imunogênica de uma proteína de M. vaccae e moléculas de DNA codificando estes polipeptídeos, junto com processos para seu uso no diagnósticos e tratamento de infecção por micobactérias. Processos para melhorar a resposta imune a um antígeno incluindo a administração de filtrado de cultura de M. vaccae ou células de M. vaccae deslipidadas são também providas.
BR9711457-0A 1996-08-29 1997-08-28 Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. BR9711457A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/705,347 US6284255B1 (en) 1996-08-29 1996-08-29 Compounds and methods for treatment and diagnosis of mycobacterial infections
US08/873,970 US6001361A (en) 1996-08-29 1997-06-12 Mycobacterium vaccae antigens
PCT/NZ1997/000105 WO1998008542A2 (en) 1996-08-29 1997-08-28 Compounds and methods for treatment and diagnosis of mycobacterial infections

Publications (1)

Publication Number Publication Date
BR9711457A true BR9711457A (pt) 2000-01-18

Family

ID=24833058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711457-0A BR9711457A (pt) 1996-08-29 1997-08-28 Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.

Country Status (11)

Country Link
US (3) US6284255B1 (pt)
EP (1) EP0939646A2 (pt)
JP (1) JP2001503969A (pt)
KR (1) KR20000037134A (pt)
CN (1) CN1235555A (pt)
AU (1) AU723606B2 (pt)
BR (1) BR9711457A (pt)
CA (1) CA2263885A1 (pt)
NZ (1) NZ334358A (pt)
TW (2) TW527360B (pt)
WO (1) WO1998008542A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432714B2 (en) * 1989-07-28 2002-08-13 Stanford Rook Limited Prophylactic and therapeutic method
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
HUP0100352A2 (hu) * 1997-12-23 2001-06-28 Genesis Research & Development Corporation Limited Mycobacterium vaccaeből származó kompozíciók és eljárások ezek alkalmazására
US6328978B1 (en) * 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US6642435B1 (en) * 1998-12-18 2003-11-04 E. I. Du Pont De Nemours And Company Plant folate biosynthetic genes
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504079A (ja) * 1999-07-12 2003-02-04 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド 感染症および免疫系疾患の治療用組成物とその使用方法
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DK2133100T3 (da) * 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
AU2002309857A1 (en) * 2001-05-11 2002-12-03 Corixa Corporation Vaccines for the treatment of autoimmune disease
US7273602B2 (en) * 2001-07-19 2007-09-25 Akira Hayashi Immunotherapy for humans
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ES2231037B1 (es) * 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
US7713715B2 (en) * 2005-09-06 2010-05-11 University Of Tennessee Research Foundation Method for diagnosing infections
ATE483973T1 (de) * 2006-10-16 2010-10-15 Thijsen Steven Frederik Theodo Cross-spot
ES2307402B1 (es) * 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CN101157722B (zh) * 2006-12-06 2010-10-20 中国农业大学 牛分枝杆菌Mce4E蛋白、其制备方法及应用
JP6054371B2 (ja) * 2011-04-06 2016-12-27 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 病原性疾患における細菌mamポリペプチドの調節
CN102707052B (zh) * 2012-05-11 2015-03-11 中国农业科学院北京畜牧兽医研究所 含重组蛋白混合物的牛结核病检测试剂
CN103981260B (zh) * 2014-05-06 2016-03-09 山东省农业科学院奶牛研究中心 一种检测气溶胶中牛分枝杆菌与结核分枝杆菌的方法
CN108743931B (zh) * 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
AU2019306543A1 (en) * 2018-07-17 2021-01-28 Humabs Biomed Sa Antibodies against campylobacter species
CN109988770B (zh) * 2019-01-10 2022-11-22 中国人民解放军第四军医大学 一种c-di-AMP合成酶单克隆抗体的重链和轻链可变区基因和编码的多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (pt) 1971-11-19 1975-02-07 Anvar
NL7308450A (pt) 1972-06-20 1973-12-27
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
DK0454735T3 (da) 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
GB8917256D0 (en) 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB9219425D0 (en) 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
EP0556248B1 (en) * 1990-11-08 1997-06-25 University College London Mycobacterium as adjuvant for antigens
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB9203814D0 (en) 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
JPH09505588A (ja) * 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
AU699007B2 (en) * 1994-03-21 1998-11-19 Rijksuniversiteit Utrecht Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use

Also Published As

Publication number Publication date
AU4036597A (en) 1998-03-19
CA2263885A1 (en) 1998-03-05
AU723606B2 (en) 2000-08-31
WO1998008542A3 (en) 1998-07-09
EP0939646A2 (en) 1999-09-08
US6410720B1 (en) 2002-06-25
WO1998008542A2 (en) 1998-03-05
JP2001503969A (ja) 2001-03-27
US6284255B1 (en) 2001-09-04
KR20000037134A (ko) 2000-07-05
TW562680B (en) 2003-11-21
US6001361A (en) 1999-12-14
TW527360B (en) 2003-04-11
NZ334358A (en) 2000-08-25
CN1235555A (zh) 1999-11-17

Similar Documents

Publication Publication Date Title
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
DE69333802T8 (de) Äusseres membranprotein von haemophilus
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
DE3650753D1 (de) Auf einmaligen sequenzen innerhalb des veränderlichen gebiets des t-zellrezeptors basierte diagnosemittel und deren verwendung
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
WO2000039299A3 (en) Streptococcus antigens
BR9909472A (pt) Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
PT95153A (pt) Processo de producao de neurotrofina-3,dos meios para o mesmo e de composicoes farmaceuticas
BR9814276A (pt) Antìgenos de superfìcie
BG101103A (bg) Теломераза при бозайници
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
WO1999042588A3 (en) Group b streptococcus antigens
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
ATE163676T1 (de) Molekulare klone von hiv-1 und deren verwendung
AU2529095A (en) Vaccine against mycobacterial infections
ATE349533T1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO1995006726A3 (en) Dna molecule encoding for cellular uptake of mycobacterium tuberculosis
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
Rosa-Fraile et al. Identification of a peptide from mammal albumins responsible for enhanced pigment production by group B streptococci

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
HKFN Application deemed withdrawn (deleted)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.